NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences beats Q2 earnings, driving Ingrezza sales up 12% while launching Cressenity and Vykat XR—boosting growth, safety and investor confidence.

Neurocrine Biosciences Q2 earnings beat forecasts, boosting Ingrezza guidance and attracting analyst upgrades – a bright outlook amid insider sales.

Neurocrine Biosciences posts Q2 2026 growth, Ingrezza revenue boost, and strategic equity moves—highlighting solid performance and a bullish outlook.

Neurocrine Biosciences’ Q2 2026 shows 21.6% revenue growth, driven by INGREZZA and VYKAT XR, with strong EPS, margins, and a new $4.3 B revenue outlook.

Neurocrine Biosciences launches a Phase 2 pediatric trial for crinecerfont (Crenessity®), aiming to replace high‑dose steroids in infants with congenital adrenal hyperplasia.

Neurocrine Biosciences files a Rule 144 notice for a senior officer’s 200‑share sale—showing routine equity‑incentive compliance, no impact on valuation, and full regulatory transparency.

Neurocrine Biosciences’ recent Rule 144 filing shows a modest officer option sale—an insider move that signals liquidity while its 75% share‑price rise underscores solid growth. Explore insider trends, strong cash, and regulatory risks that shape it…

Neurocrine Biosciences shows new long‑term data for VYKAT XR and CR NESSITY, boosting market access, pricing strategy, and M&A prospects in rare endocrine diseases.

Neurocrine’s latest INGREZZA data shows high remission rates and safety in hepatic‑impaired and IDD patients, boosting payer value, market share, and growth prospects before the 2030s patent cliff.

Neurocrine Biosciences’ May 29, 2026 insider trades show senior staff buying shares, exercising NQSOs and RSUs, and filing a Rule 144 to boost liquidity—transparent moves that underscore strong governance and regulatory compliance in the biotech sec…